+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
532039 ZENOTECH

Zenotech Laboratories Share Price

 

 

Zenotech Laboratories live price: ₹45. It opened at ₹44 vs previous close ₹45; intraday high/low: ₹46/₹44. The 50 & 200 DMA stand at ₹44.74/₹48.34.

Zenotech Laboratories Performance

  • Today's Low
  • ₹44
  • Today's High
  • ₹46
  • 52 Week Low
  • ₹34
  • 52 Week High
  • ₹67
  • Open Price₹44
  • Previous Close₹45
  • Volume7,984
  • 50 DMA₹44.74
  • 100 DMA₹45.40
  • 200 DMA₹48.34

Zenotech Laboratories Chart

Investment Returns

  • Over 1 Month + 3.19%
  • Over 3 Month -0.18%
  • Over 6 Month -3.87%
  • Over 1 Year -28.2%

Smart Investing Starts Here Start SIP with Zenotech Laboratories for Steady Growth!

Invest Now

Zenotech Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -256.2
  • PEG Ratio
  • 2.1
  • Market Cap Cr
  • 275
  • P/B Ratio
  • 2.8
  • Average True Range
  • 2
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.03
  • RSI
  • 50.75
  • MFI
  • 58.68

Latest Stock News Updates

Zenotech Laboratories Q3 Results 2025 on 30 Jan, 2025: profit falls by 49.7% YOY, profit at 1.69 crore and revenue at 11.24 crore

Zenotech Laboratories Q3 Results 2025 on 30 Jan, 2025: Revenue increased by 2.74% YoY & profit decreased by 49.7% YoY, profit at 1.69 crore and revenue at 11.24 crore

Zenotech Laboratories Q3 FY24 Results Live: Profit Rises by 143.21% YoY

Zenotech Laboratories Q3 FY24 Results Live: Revenue Increased by 24.41% YoY & Profit Increased by 143.21% YoY

Zenotech Laboratories Financials

Zenotech Laboratories Technicals

EMA & SMA

Current Price
₹45.00
+ 0.31 (0.69%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 10
  • 20 Day
  • ₹44.84
  • 50 Day
  • ₹44.74
  • 100 Day
  • ₹45.40
  • 200 Day
  • ₹48.34

Resistance and Support

44.87 Pivot Speed
  • R3 47.03
  • R2 46.27
  • R1 45.63
  • S1 44.23
  • S2 43.47
  • S3 42.83

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Zenotech Laboratories has an operating revenue of Rs. 43.61 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 10% is healthy, ROE of -1% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 16 which is a POOR score indicating inconsistency in earnings, a RS Rating of 36 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 70 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Zenotech Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-04-29 Audited Results
2026-01-23 Quarterly Results
2025-10-31 Quarterly Results
2025-07-28 Quarterly Results
2025-04-25 Audited Results

Zenotech Laboratories Shareholding Pattern

68.84%
0.01%
22.81%
8.34%

Zenotech Laboratories FAQs

Zenotech Laboratories share price is ₹45 As on 04 June, 2026 | 18:54

The Market Cap of Zenotech Laboratories is ₹274.6 Cr As on 04 June, 2026 | 18:54

The P/E ratio of Zenotech Laboratories is -256.2 As on 04 June, 2026 | 18:54

The PB ratio of Zenotech Laboratories is 2.8 As on 04 June, 2026 | 18:54

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23